electroCore, based in Basking Ridge, New Jersey, is releasing in the U.S. its latest device for treating pain related to migraines and episodic cluster headaches. The gammaCore Sapphire, cleared by the FDA, uses the same non-invasive vagus nerve stimulation technology as the original gammaCore device, but is smaller and more modern looking, features more pleasant electrodes, a bigger and brighter screen, and intensity buttons on the side for easier control during therapy sessions.
The gammaCore is placed against the neck in the vicinity of the vagus nerve, which it stimulates to help control symptoms of migraines and cluster headaches. Though it’s not a drug, the device does require recurring prescriptions from the doctor to continue receiving therapy, maybe even for years. To avoid patients using it beyond the prescribed time, the gammaCore Sapphire requires the an RFID chip, sent in the mail with every prescription, near the device to activate it for another month.
GammaCore Sapphire offers more convenience to patients with an enhanced designed and added functionalities that make the therapy application more seamless and even more patient-centric than the device’s previous generation,” said Dan Duhart, Chief Commercial Officer of electroCore. “Constantly innovating to deliver the next-generation device is just one example of our commitment to providing relief to patients suffering from the debilitating pain of migraine and episodic cluster headache.”
gammaCore Sapphire Helps Control Migraines and Cluster Headaches: Now Available in U.S. [Medgadget]